Background Albuminuria represents a biomarker for cardiovascular disease risk and a predictor of chronic kidney disease onset. Increased urinary albumin excretion is a sign of systemic vascular illness, which includes arterial stiffness, myocardial capillary dysfunction, and kidney injury. An elevated risk for micro-vascular disease, coronary artery disease, stroke, heart failure (HF), and arrhythmias associated with albuminuria. Nowadays, a number of substances can diminish albuminuria and lower the cardiovascular disease risk however, there is still little albuminuria screening. Aim Understand albuminuria occurrence in patients with established HF to ascertain the association between HF class and albuminuria and demonstrate that albuminuria is reversible with HF medication. Patients and methods The upcoming research involved 100 participants diagnosed with impaired systolic function; albuminuria was estimated by urinary albumin/creatinine ratio in two random urine samples before and after improvement. Two groups of patients were formed. Group A: patients with albuminuria being measured before and after improvement of HF manifestations. Group B: patients without albuminuria being measured before and after improvement of HF manifestations. Results Micro-albuminuria presented in one-third of HF patients, with no correlation between albuminuria and HF class. After HF medication, there was a significant drop in albuminuria. Conclusion Micro-albuminuria presented in 36% and macro-albuminuria in 12% of HF patients, mostly had diabetes, hypertension, or decreased estimated glomerular filtration rate. After treatment, albuminuria significantly improved without discernible relationship to HF class. Further testing for underlying renal impairment is necessary if persistent albuminuria after treatment.
Khattab et al. (Wed,) studied this question.